JP2017531699A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531699A5 JP2017531699A5 JP2017540976A JP2017540976A JP2017531699A5 JP 2017531699 A5 JP2017531699 A5 JP 2017531699A5 JP 2017540976 A JP2017540976 A JP 2017540976A JP 2017540976 A JP2017540976 A JP 2017540976A JP 2017531699 A5 JP2017531699 A5 JP 2017531699A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- hpv
- use according
- vaccine
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068332P | 2014-10-24 | 2014-10-24 | |
| US62/068,332 | 2014-10-24 | ||
| PCT/US2015/057150 WO2016065281A1 (en) | 2014-10-24 | 2015-10-23 | Cancer and skin lesion treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531699A JP2017531699A (ja) | 2017-10-26 |
| JP2017531699A5 true JP2017531699A5 (enExample) | 2018-11-15 |
| JP6663438B2 JP6663438B2 (ja) | 2020-03-11 |
Family
ID=55761638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540976A Active JP6663438B2 (ja) | 2014-10-24 | 2015-10-23 | 癌および皮膚病変の治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10238729B2 (enExample) |
| EP (1) | EP3209676A4 (enExample) |
| JP (1) | JP6663438B2 (enExample) |
| KR (1) | KR102285401B1 (enExample) |
| CN (1) | CN107001430A (enExample) |
| AU (1) | AU2015335652B2 (enExample) |
| BR (1) | BR112017008280A2 (enExample) |
| CA (1) | CA2965498A1 (enExample) |
| CL (1) | CL2017001008A1 (enExample) |
| IL (1) | IL251825B2 (enExample) |
| MX (1) | MX395186B (enExample) |
| MY (1) | MY195018A (enExample) |
| PH (1) | PH12017500754A1 (enExample) |
| SG (1) | SG11201703262UA (enExample) |
| WO (1) | WO2016065281A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN122399006A (zh) * | 2016-02-27 | 2026-07-17 | 哈普威克斯有限责任公司 | 使用疫苗治疗癌症或皮肤病变的方法和组合物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60126737T2 (de) * | 2001-03-23 | 2007-11-08 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff |
| GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
| US20060222656A1 (en) * | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| GB0206359D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0222953D0 (en) * | 2002-10-03 | 2002-11-13 | Glaxo Group Ltd | Novel Compounds |
| PT1572233E (pt) | 2002-12-20 | 2011-06-07 | Glaxosmithkline Biolog Sa | Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
| KR20070029254A (ko) * | 2004-06-16 | 2007-03-13 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신 |
| US8399610B2 (en) | 2004-08-05 | 2013-03-19 | University College Cardiff Consultants Limited | HPV vaccine comprising peptides from host cell proteins |
| GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| AU2008226974B2 (en) * | 2007-03-09 | 2013-08-15 | Merck Sharp & Dohme Llc | Papillomavirus vaccine compositions |
| CN101530614A (zh) * | 2008-03-10 | 2009-09-16 | 北京康乐卫士生物技术有限公司 | 五价重组人乳头瘤病毒疫苗 |
| CN101530612A (zh) * | 2008-03-10 | 2009-09-16 | 北京康乐卫士生物技术有限公司 | 16型重组人乳头瘤病毒疫苗 |
| US20110110979A1 (en) | 2008-04-16 | 2011-05-12 | Universite De Lausanne | Method and vaccine for optimizing the specific immune responses |
| EP2416798B1 (en) * | 2009-04-10 | 2017-09-20 | The Johns Hopkins University | Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines |
| CN107252489A (zh) * | 2009-04-13 | 2017-10-17 | 法国健康和医学研究院 | Hpv颗粒及其用途 |
| CN101890160B (zh) * | 2009-04-28 | 2014-06-18 | 北京康乐卫士生物技术有限公司 | 多价重组人乳头瘤病毒疫苗及其应用 |
| US9566323B2 (en) | 2009-06-19 | 2017-02-14 | Eyegene Inc. | Vaccine for cervical cancer |
| CA2768172A1 (en) * | 2009-06-25 | 2010-12-29 | Glaxosmithkline Biologicals S.A. | Novel compositions |
| AR074485A1 (es) * | 2009-12-04 | 2011-01-19 | Consejo Nac Invest Cient Tec | Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos |
| JP2014516075A (ja) * | 2011-06-06 | 2014-07-07 | シェブロン フィリップス ケミカル カンパニー エルピー | 癌治療のためのメタロセン化合物の使用 |
| US20130064849A1 (en) * | 2011-07-14 | 2013-03-14 | The Board Of Regents Of The University Of Texas | Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines |
| CN104203270A (zh) * | 2012-03-18 | 2014-12-10 | 葛兰素史密丝克莱恩生物有限公司 | 针对人乳头状瘤病毒的接种方法 |
| WO2013149017A1 (en) * | 2012-03-28 | 2013-10-03 | Kansas State University Research Foundation | Vaccine adjuvant |
| US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP3054994A4 (en) | 2013-10-13 | 2017-10-11 | The Board of Trustees of the University of Arkansas | Human papilloma virus therapeutic vaccine |
-
2015
- 2015-10-23 CA CA2965498A patent/CA2965498A1/en active Pending
- 2015-10-23 EP EP15853497.4A patent/EP3209676A4/en not_active Ceased
- 2015-10-23 IL IL251825A patent/IL251825B2/en unknown
- 2015-10-23 MY MYPI2017000594A patent/MY195018A/en unknown
- 2015-10-23 CN CN201580064634.6A patent/CN107001430A/zh active Pending
- 2015-10-23 US US14/921,648 patent/US10238729B2/en active Active
- 2015-10-23 AU AU2015335652A patent/AU2015335652B2/en active Active
- 2015-10-23 BR BR112017008280-2A patent/BR112017008280A2/pt not_active Application Discontinuation
- 2015-10-23 WO PCT/US2015/057150 patent/WO2016065281A1/en not_active Ceased
- 2015-10-23 MX MX2017005418A patent/MX395186B/es unknown
- 2015-10-23 JP JP2017540976A patent/JP6663438B2/ja active Active
- 2015-10-23 KR KR1020177013441A patent/KR102285401B1/ko active Active
- 2015-10-23 SG SG11201703262UA patent/SG11201703262UA/en unknown
-
2017
- 2017-04-24 PH PH12017500754A patent/PH12017500754A1/en unknown
- 2017-04-24 CL CL2017001008A patent/CL2017001008A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guo et al. | Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial | |
| Lin et al. | Therapeutic hpv DNA vaccines | |
| Wu et al. | Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation | |
| EP3095798B1 (en) | Immunity enhancing therapeutic vaccine for hpv and related diseases | |
| JP2015533376A5 (enExample) | ||
| JP2016537417A5 (enExample) | ||
| JP2017502081A5 (enExample) | ||
| Tran et al. | Spontaneous regression of metastatic melanoma after inoculation with tetanus–diphtheria–pertussis vaccine | |
| JP2010530362A5 (enExample) | ||
| JP7460094B2 (ja) | 子宮頸がんの治療方法 | |
| Ding et al. | Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer | |
| JP2018509423A5 (enExample) | ||
| JP6663438B2 (ja) | 癌および皮膚病変の治療 | |
| Wang et al. | The role and development of peptide vaccines in cervical cancer treatment | |
| EP4196157A1 (en) | Compositions for treating gastrointestinal adenocarcinomas by altering the tumor microenvironment | |
| RU2832963C2 (ru) | Способ лечения рака шейки матки | |
| HK1241898A1 (en) | Cancer and skin lesion treatment | |
| Kumar et al. | The Current Landscape for Human Papillomavirus Vaccination in Oropharyngeal Carcinoma | |
| Aremu et al. | Immunotherapy for head and neck cancers | |
| Melief | Peptide-based therapeutic cancer vaccines | |
| Elliott | Human Papillomavirus 9-valent Vaccine, Recombinant (Gardasil® 9) | |
| Alfonso et al. | Biological activity of LALF32-51–E7, a vaccine candidate for the treatment of anogenital lesions associated to HPV16 | |
| Marron et al. | 289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting | |
| BR112022021284B1 (pt) | Composição farmacêutica, seu uso para tratar ou prevenir um câncer induzido pelo vírus do papiloma humano, e combinação | |
| Poon et al. | A MULTI-CENTER PHASE II TRIAL OF BEVACIZUMAB (B) PRE-AND POST-TRANSARTERIAL CHEMOEMBOLIZATION (TACE) TREATMENT FOR PATIENTS WITH LOCALIZED UNRESECTABLE HCC: INTERIM SAFETY REPORT: 1744 |